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1. Introduction
No scientist can escape being fascinated by the complexity of the interplay between innate and
adaptive immunity in order to monitor tissue homeostasis, to protect against infectious
pathogens and to eliminate damaged cells. One of the most important tasks of the Immune
System is to distinguish between “self” and “foreign”. Cancer is formed of cells that suffer
several mutations but form still part of the individual body. All types of cancer are caused by
the progressive growth of the progeny of a single transformed cell. Curing this disease requires
that all the malignant cells have to be removed or destroyed without damaging the patient. To
achieve this task the own body has to distinguish between the cells of “the tumor” and their
“other cellular” counterparts.
The initial thought that the immune system has indeed a protective role in tumor development
has changed enormously in the past years. In the last few years, it has been experimentally
shown that the Immune system itself can facilitate tumor development and progression and
functions to promote or select tumor variants with reduced immunogenicity.
Decades of intensive investigation have made it increasingly clear that the interplay between
immunity and cancer is complex. Next, there is some information about how the immunosur‐
veillance hypothesis has been confronted through all these years since the early 70’s [1].
2. Immunosurveillance hypothesis confrontation
The first approach to the interplay between cancer and the Immune system, was done by
Stutman. He used nude mice and methylcolantreno (MCA) to produce tumors in both, nude
and their wild type counterparts [2]. The conclusion was that nude mice did not form more
chemically induced tumors compared with the controls, nor did they show a shortened tumor
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latency period after carcinogen injection. The similarity between immune-competent and nude
mice was consistent in subsequent experiments that employed mice of different ages, different
doses of carcinogen, etc. These findings were also supported by Rygaard who showed no
differences in tumor formation in a study of 10 800 nude mice over a period of 5-7 months [3].
It is now clear that nude mice are not completely immunocompromised since they have
detectable populations of functional αβ T cell receptor bearing lymphocytes [4]. Furthermore,
these studies were done before the discovery of NK cells, which are thymus independent and
∂γ T cells, a subset of lymphocytes which may develop extrathymically. Later on, experiments
based also on models of MCA–induced tumor formation showed that mice lacking either the
IFN¥ receptor or STAT1, the transcription factor essential for the signalling of IFN¥ receptor,
were found to be 10-20 times more sensitive than wild-type mice to the MCA tumor formation
[5]. In studies of mice lacking the TCRβ chain or the TCRγ chain, MCA treatment of either mice
increased the incidence of fibrosarcomas as compared with controls, showing that both T cells
subsets are critical for protecting in this particular model of tumor development.
Shankaran in 2001 used targeted mice that lack RAG-1 or RAG 2 (recombination activating
gene). These enzymes are essential for the repair of double stranded DNA breaks and they are
solely in the lymphoid compartment. All this means that RAG deficient mice fail to rearrange
lymphocyte antigen receptors and lack of NKT, T and B cells. When these mice were injected
with MCA, 26 of 26 RAG deficient mice developed sarcomas. In contrast, 5 of 20 wild type
mice developed spontaneous neoplásia [6].
The previous experiments show clearly the participation of some components of the Immune
System in order to avoid the formation of tumors. However, these results are specifically for
the MCA model, where its carcinogenesis mechanism is different from all the other types of
cancer. Even more, these findings were obtained in murine models. However, if cancer
immunosurvellience exists in mice, does exists in humans?
3. Is this immune protection similar in humans?
Scientist turned back to look if immunodeficient or immunosuppressed patients and individ‐
uals with primary immunodeficiencies had greater incidences of cancer. Early studies of
transplanted patients who were subjected to immunosuppressive agents actually showed
higher relative risk for cancer development. The answer was affirmative but, most of this
higher risk was due to the development of tumors that were of viral origin. For example, non-
Hodgking’s lymphoma, Kaposi’s sarcoma and carcinomas of the genitourinary and anogenital
areas where all of these are linked to infection with Epstein-Barr virus, human herpesvirus 8
and HPV. A review of data from thirty years of Transplant Tumor Registry found that
transplanted patients showed two times more relative risk to develop melanoma over the
general population [7].
It has also been reported that there is evidence showing a positive correlation between the
presence of lymphocytes in a tumor (TILs) and an increase in the patient’s survival. Sorting
more than 500 patients with primary melanoma who had more than 7 years of follow up,
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showed that patients in the brisk tumor infiltrating lymphocytes response survived two times
longer than patients absent of TILs in their tumors. Later on, researchers reported the same
prognostic correlation when studied the presence of TIL’s in melanomas that had metastasized
to lymph nodes [8]. The previous studies show that the presence of lymphocytes in the tumor
may increase life survival. However, these patients after some time still die due to the
progression and migration of melanoma to other vital organs, therefore, the Immune system
do not resolve the tumor.
4. Cancer occur in immunocompetent individuals
The protective role of the Immune System is not completely effective to eliminate tumors. In
order to explain this failure, it has been proposed that three stages exist in humans during this
process: a) Elimination, where the Immune system is capable of destroying neoplastic cells by
the innate immunity effectors; b) Equilibrium, specific effectors that eliminate the tumor are
induced but, at the same time, selective pressure is generated on tumor cells, as a result mutated
neoplastic variants occur; c) Escape, the tumor variants that survive become more resistant to
identification and/or elimination by the Immune System and consequently the tumor grows.
This process has been called “Cancer immunoediting” to describe more accurately the dual
host-protecting and tumor sculpting actions of the Immune System shaping a neoplastic
disease.
This hypothesis explains the observation that tumors often become clinically evident years
after their molecular origin. At the end of this equilibrium between the immune system and
tumor growth, the immune response allows for the outgrowth of a subpopulation of tumor
cells. Factors contributing early neoplastic cells to survive, grow and invade are released by
the immune system itself.
The major tumor type that occurs with increased frequency in immunodeficient individuals
are virus-associated tumors, so immune surveillance is critical for control of this type of
tumors, while the immune system does not normally respond to the neoantigens derived from
the multiple genetic alterations in spontaneously arising tumors. Studies in mice have also
revealed that when these are induced for immunodeficiency, show a high susceptibility to
virally induced tumors and a greater tendency to develop spontaneous lymphomas compared
with immunocompetent mice [8].
5. Does the immune system control each type of cancer?
All types of cancer share several characteristics, some of the most studied are uncontrolled
growth, resistance to apoptosis, motility, proteolytic capacity and adhesion. However, each
type of cancer also may have completely different etiologies (physical, chemical and/or
biological), cell type of origin, mechanism of transformation, anatomical localization, histolo‐
pathological features, mortality rate, tumor markers, etc.
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6. Melanoma: Its origins and incidence
Melanoma, an aggressive malignancy arising from melanocytes, is one of the most lethal of all
skin cancers due to its great capacity to produce metastasis and its high chemoresistance [9].
It causes approximately 80% of skin cancer related deaths worldwide and is considered to be
the most common mainly fatal malignancy of young adults mainly in Europe, Australia, New
Zealand and United States of America where many people is red-haired with blue or green
eyes. This disease is predominantly of populations with lighter skin color (Fitzpatrick I, II III)
and the incidence is around tenfold lower in populations with darker skin color (Fitzpatrick
IV, V and IV). The list of risk factors in developing melanoma is long but the main risk factors
are: blond or red hair, numerous freckles and tendency to burn and tan poorly.
Over the past 55 years, the incidence of melanoma in most developed countries has risen faster
than any other cancer type. Incidence rose dramatically between 1950 and 2000 (approximately
10% every year) particularly in some countries where caucasian population are. Melanoma
provides one of the best examples of how genetics and environment interact in the pathogen‐
esis of cancer. Incidence is strongly related to race and geographic location [10].
Primary melanoma progresses generally through two phases: a) the radial growth phase, is
the horizontal spreading of transformed melanocytic cells inside the epidermis and small
groups of invasive cells limited to the upper part of the dermis, and b) the vertical growth
phase, is the invasion of melanoma cells into the deeper dermis and subcutaneous tissues.
7. Primary melanoma development
Most melanomas (with the exception of acral melanomas) are caused by exposure to UVB. This
radiation can damage melanocyte DNA, causing hundreds of mutations including in genes
controlling cell cycle progression and signal transduction pathways. UVB radiation may
induce pyrimidine dimers, primarily thymidine di-nucleotides. So, lesions not repaired by
nucleotide excision repair can lead to GC---→AT transitions, leaving a mutagenic mark. The
epidemiological evidence for a role of solar exposure in melanoma (especially in Caucasian
populations) is very strong. Some studies have suggested that total accumulated exposure to
sun is a very important factor whereas long-term occupational exposure may be protective.
UV irradiation induces also morphological and functional alterations in epidermal Langer‐
hans’ cell. The involvement of TNFα in the emigration of Langerhans’ cells from UV-exposed
skin into the regional lymph nodes has been reported. However, it may exist other non-
mutagenic mechanisms involved such as immune suppression, UV induction of melanocyte
growth factors by damaged keratinocytes, or UV production of mutagenic oxidative radicals
during inflammation. UVB, can also weaken both the innate and adaptive immune systems
by promoting the release of IL-10 by Langerhans cells [11] and by favoring the infiltration of
IFNγ-producing macrophages. These cytokines possess activities as immunosuppressive and
pro-angiogenic respectively [12].
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It is important to mention that there are different molecular subtypes of melanomat, which
may show a totally different antigenic profile depending on the number and quality of genetic
alterations. These subtypes are superficial spreading, lentigo maligna, nodular and acral
melanoma. The phenotype of malignancy is a reflexion of genetic events altering the RNA and
protein expression patterns of normal cells. It has been observed that in general all metastatic
melanoma generally displays resistance to treatment with antineoplastic drugs. Additionally,
these therapies are severely toxic to the patients and their side effects include fatigue, malaise
and a higher risk for non-melanoma cancers [13]. Superficial spreading melanoma is the most
common melanoma in the first world countries and can occur at any site and at any age. About
80% of superficial spreading melanoma occur de novo. The classic lesions show variation in
pigmentation and pagetoid spread of melanoma cell in epidermis [14]. Superficial spreading
melanomas usually occur in younger patients than nodular or lentigo malign melanomas. They
typically involve intermittently sun-exposed anatomical sites such as the trunk, back and
extremities.
8. From melanocyte to melanoma
The epidermis contains keratinocytes and two types of dendritic cells, a) Langerhans’ cells
which are professional presenting cells playing an essential role in cellular response mainly to
microorganisms but apparently also to tumor antigens; and b) melanocytes. Langerhans’ cells
are located in the suprabasal layer of the epidermis, whereas melanocytes are located amongst
the basal layer of the epidermis, hair bulb, eyes, ears and meninges. Melanin pigment is
produced by melanocytes in their specific cytoplasmic organelles called melanosomes.
Melanin pigment synthesis by each melanocyte is transferred to an average of 36 keratinocytes.
The transferred melanin forms a cap at the top of nucleous of mitotically active basal cells and
prevent the UV damaging effects on nucleus.
Melanoma arises through a complex process of cellular mutations and a loss of keratinocyte
control over growth and differentiation [15]. As malignant melanoma progresses, it develops
through interaction between dysfunctional melanocytes and the tumor microenvironment.
This progression is accompanied with changes in both keratinocytes and local adhesion
molecules allowing for the formation of nevocyte nests at the dermal-epidermal junction [16].
As mentioned earlier, the progression from healthy melanocyte to melanoma occurs through
both mutations within the tumor and through alterations of the cellular environment around
the melanoma. In the skin, tissue homeostasis is critical in cellular regulation as well as immune
control, and melanoma disrupts this regulation through multiple processes. Differentially
expressed genes that are mutated during this multistep process conduct towards the trans‐
formation of melanocytes to melanoma. A great number of genes and proteins have been
reported to play an essential role in this transformation. Some of these are listed: BRAF, cKIT,
PTEN, p16,p53, cyclin1, ARF, K-RAS. Differentially expressed genes between melanocytes and
melanoma cells impact in the expression of somehow “different” surface membrane expres‐
sion of certain proteins (TAAs) that may play an important role for immune recognition and
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their elimination. In addition to mutation-derived tumor associate antigens (TAAs), melanoma
is known to express normal, melanocytic lineage-related antigens (gp100, MART-1) that are
not recognized by the immune system owing to some form of tolerance to self antigens [17].
9. The immune system in health
The immune system is highly elaborated, with a diversity of stop and go mechanisms essential
to accomplish different tasks. It is composed of many cell types and mediators that interact
with non-immune cells in a complex and dynamic way to ensure protection against foreign
pathogens but at the same time maintaining tolerance to self-antigens (such as tumor cells in
a way). The immune system has two completely different compartments –adaptive and innate,
differing these on antigen specificity, timing of activation and cellular composition. These cells
have communication networks that allow rapid responses to tissue injury. Innate immune
cells, such as dendritic cells (DC) natural killer (NK) cells, macrophages, neutrophils, baso‐
phils, eosinophils and mast cells are the first line of defense against foreign antigens and
damaged cells.
10. The innate immune system and inflammation
When tissue homeostasis is broken, sentinel macrophages, DC and mast cells release cytokines,
chemokines, matrix remodeling proteases (MMP) and reactive oxygen species (ROS), inducing
migration and infiltration of more leukocytes into damaged tissue, this process is called
inflammation. Although inflammation is important in tissue repair and erradication of harmful
pathogens, unresolved, chronic inflammation that happens when the offending agent is not
removed, can be detrimental to the host. Immune cells infiltration in the absence of pathogens
is also characteristic of cancer, and these cells can definitely influence the growth and pro‐
gression of this disease. The destructive cycles that are initiated inside the tissues by failure to
commit either arm of the immune system, can result in excessive tissue remodeling, loss of
tissue architecture due to tissue destruction and finally DNA and protein alterations due to
oxidative stress.
So, one might question, why does inflammation potentiate cancer development rather than
protect against it. Neoplastic microenvironments enhance chronic pro-tumorigenic inflam‐
matory state [18]. The inflammatory microenvironment of neoplastic tissues is characterized
by the presence of host leukocytes both in the supporting stroma and among the tumor cells,
with macrophages, dendritic cells, mast cells, and T cells being differentially distributed [19].
Macrophages represent up to 50% of the tumor mass and are key cells in chronic inflammation.
These cells constitute an extremely heterogeneous population, which differentiate into distinct
macrophages types, identified as M1 (or classically activated) and M2 (or alternatively
activated) [20]. These cells respond to microenvironment signals with polarized functional
programs [21]. M1 type macrophages produce Th1 cytokines and predominate in earlier stages
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of the disease. In contrast, M2 type macrophages secrete factors which favor immunosuppres‐
sion and tumor development, so they prevail in more advanced disease. Initially, these
cytokines have regulatory roles in the tumor microenvironment through growth inhibition,
but these functions are lost as tumors slowly progress to a state of immunosuppression. This
is the case for IL-6 when is released during initial tumor formation by keratinocytes and
macrophages inhibits tumor proliferation. However, in late stages of melanoma progression
undergoes transition to stimulator [22].
Mutations and genetic polymorphisms in crucial genes that regulate cytokine function,
metabolism and leukocyte survival have also been implicated as aetiological factors in chronic
inflammation [23]. Population based studies reveal that individuals who are prone to chronic
inflammatory diseases have an increased risk of cancer development [24].
11. The adaptive immune system and melanoma
Melanoma usually remains refractory to immunologic control even when these cells are
relatively immunogenic compared to other cancer types. Being melanoma a disease generated
by autologous cells, should be possible to instruct the organism to fight against it?
The adaptive immune system is composed of the antigen presenting cells (APC) that include
dendritic cells (DC), the most effective APCs and CD4+ and CD8+ T cells. CD4+ T cells include
both T helper and regulatory T cell (Treg) populations. In order to initiate an adaptive immune
response, APC can activate T cells by efficiently processing exogenous as well as endogenous
antigens and present them to T cells through the major histocompatibility complex (MHC). T
cells recognize their targets by detecting peptide fragments derived from these foreign or
damaged proteins. There are two types of MHC, class I and II. One of the most important
features of both molecules is an outer extracellular domain that forms a long pocket in which
peptide fragments are located. The most important differences between the two classes of
MHC molecules are in the source of the peptides they contain and carry to the cell surface.
CD8+ and CD4+ T cells interact with melanoma through contact with MHC class I and II on
their cell surface, respectively.
12. Defects in antigen processing and presentation
Presentation of tumor-associated antigens (TAA) on MHC class I by APCs is a crucial step for
the differentiation and expansion of CD8+ T cells against TAAs and the eventual destruction
of tumor cells.
Melanoma cells have been observed to downregulate MHC class I expression, so preventing
any T cell activation and tumor elimination [25]. This tumor has strategies to avoid CD8+
detection and activation. There is clinical evidence that support this statement, since patients
with metastatic melanoma show detectable CD8+ T cells specific for melanoma antigens,
Interaction Between the Immune System and Melanoma
http://dx.doi.org/10.5772/54939
59
however, the tumor is not eliminated [26]. Other mechanisms that have been described in this
context in melanoma include downregulation of MHC class II antigens [27]. One example is
the low expression of HLA-DM, a nonclassical Class II MHC responsible for peptide loading
into MHC class II and the removal of the invariant chain li peptide (CLIP) [28]. Melanoma cells
also differentially express acidic cathepsins which process endogenous and exogenous
antigens in endolysosomal compartments. Their limited activity results in poor Ag processing
and the generation of useless antigenic determinants, which are unable of stimulating T cells
[29]. Melanoma also has been found to lack the IFN∂-inducible lysosomal thiol reductase
(GILT), essential enzyme for the functional reduction of cysteinylated or oxidized proteins and
peptides. The presence of GILT in endolysosomal compartments enhances the acidic cathepsin
processing of TAAs and MHC class II components, and the functional processing of cystein‐
sylated or oxidized peptides for an excellent CD4+ T cell activation. All these defects result in
the presentation of a range of nonfunctional peptides which fail to stimulate interacting CD4+
cells, limiting the effects of CD8+ cytotoxic responses.
13. Failure in costimulatory signals
After the Ag processing and the loading of tumor derived peptides into the MHC class II
groove, this complex is translocated to the cell surface for presentation to T cells. CD4+ T cells
recognize functional class II complexes with antigenic peptides and tight junction binding
occurs between the TCR and the class II/Ag complex. CD4+ molecules on T cells then bind to
a different site on the MHC class II molecule and T cells receive their first stimulation signal
[30]. A second signal is required for activation of the T cell. If the T cells receive a stimulatory
signal from the tumor in the form of CD80/CD86 (B7-1, B7-2) binding to T cell expressed CD28,
then T cells become activated and may give an anti-tumor response. The most studied immune
checkpoint molecule in activated T cell is CTLA-4. It is a high affinity receptor for the ligand
B7 expressed by APCs. Ligation is thought to deliver an inhibitory signal, in contrast to CD28.
CTLA-4 blockade is thought to act primarily by increasing effector T-cell function.
Coestimulatory molecules are often modified on melanoma cells inhibiting T cell activation,
since it has been shown to express high levels of CTLA-4 [31]. Tumors exploit this process,
functionally silencing CD4+ T cell activation and shifting the environment to a T regs setting.
Coinhibitory signaling pathway mediated by PD-1 ligand is expressed by activated T cells. It
is considered a marker of T cell exhaustion, as engagements by its ligands PDL-1 (B7-H1] and
PDL-2 results in T cell inhibition and apoptosis. Of particular interest is the finding that tumor-
infiltrating or peri-tumoral lymphocytes in melanoma patients express PD-1 and have
impaired effector function [32]. Study shows that melanoma expresses high levels of the ligand
for PD-1, PD-1L which during TCR-MHC interaction sends a death signal to both CD4+ and
CD8+ T cells causing them to undergo apoptosis [33]. A number of different subtypes of cancer,
as well as lymphocytes and APCs in the tumor environment have also been shown to express
ligands for PD-1 which may act to suppress PD-1 expressing T cells [34].
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14. Immunosupressive tumor microenvironment and cytokines
An upregulation of immunossupressive cytokines such as IL-6, IL-10, TNFα, TGFβ and VEGF
is promoted by melanoma microenvironment. The release of these cytokines attracts immu‐
nossupressive cells: myelo-derived suppressive cells, tumor associated macrophages, or
tolerogenic DCs in the tumor microenvironment.
Polak reported that melanoma cells, melanoma recruited myeloid suppressor cells and Tregs
actively secrete IL-10 to induce tolerized T cells and DC. [35] They showed tolerogenic DCs
and Tregs present in all stages of disease progression. However, the expression of IL-10 and
IDO increased with melanoma progression with the highest production in positive lymph
nodes. Their work also suggests that TGFβ2 renders DCs tolerogenic, although for the case of
lymph nodes, IDO and TGFβ1 have a higher impact. This mechanism of tumor-associated
immunosuppression probably inhibits the immune response to the tumor and may explain
the discrepancy between the induction of systemic immunity by anti-melanoma vaccines and
their poor impact in the clinic.
It has also been reported that PGE2 is produced by melanoma associated fibroblasts and
immature  myeloid  cells.  Luft  found that  immature  monocytes-derived DC that  encoun‐
tered pro-inflammatory cytokines in the presence of PGE2 acquired migratory capacity, but
secreted low levels of cytokines. This suggest that not all mature stages of DCs are destined
to  migrate  to  lymphoid  organs  and  the  sequence  in  which  stimuli  are  encountered
significantly affects which functions are expressed [36]. Additionally, PGE2 inhibits NK T
cells  activity,  once  more  resulting  in  changes  in  the  tumor  microenvironment  towards
immunossupression [37]. COX-2 is a multifunctional enzyme that is involved in prostaglan‐
din biosynthesis, and it is upregulated in neoplastic tissues [38]. In several human epithelial
cancers,  expression of  COX-2 correlates with poor prognosis.  The crucial  molecules that
mediate these effects are not yet known, though they might include the PGE2 receptor EP2
subtype (PTGER2) [39].
15. Upregulation of regulatory T cells
Regulatory Tregs comprise 5% to 10% of the total peripheral CD4+T cell population. The
main role of Tregs is to inhibit  cytotoxic T cell  response against self-antigens and main‐
tain systemic tolerance to self-antigens. Tregs constitutively express CD25 (IL-2 receptor α
chain) on their  cell  surface and suppresses CD4+ and CD8+ effector T cells  through the
release of immunosuppressive molecules, consumption of IL-2 and direct cell to cell contact
[40].  The shift  to  tumor progression results  in  part,  from the alteration in the type and
characteristics  of  TILs  within  the  tumor.  These  changes  include  the  enhancement  of
CD4+CD25+FoxP3+Tregs, since in melanoma, particularly in advanced disease states, Tregs
are the primary infiltrating lymphocyte where they inhibit all antitumor activity through
direct contact inhibition, and the release of high levels of IL-10 [41]. Once activated these
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cells,  are  anergic  and  are  able  to  block  the  proliferation  of  effector  cells.  A  study  sug‐
gests  that  high serum concentrations  of  Tregs  are  associated with  poor  prognosis,  poor
treatment  responses  and an  increased  risk  of  recurrence  [42].  Human studies  depleting
Tregs prior to adoptive cell transfer (ACT) improved the effectiveness of treatment. Patients
challenged  with  melanoma  antigen  peptides,  MelanA/MART-1  and  gp-100,  developed
significant induction of peptide specific CD8+ T cells in 90% of them. This study shows
that  depletion  of  Tregs  in  vivo,  results  in  enhanced  immune  functions  and  substantial
development of antigen-specific CD8+ T cells in vaccinated individuals [43]. Tregs may be
harmful  for  individuals  fighting  tumors,  since  under  these  circumstances  the  immune
system  needs  maximal  activation,  but  as  common  tumor  antigens  are  largely  self-anti‐
gens, suppression of potentially self-reactive T cells by Tregs may be counterproductive in
this specific process.
16. Melanoma, an abberrant HLA-G expression
It  was  previously  mentioned  that  loss  or  down-regulated  of  classical  MHC  class  I  on
melanoma cells is one of the most important mechanisms enabling tumor cells to escape
from  immune  anti-tumor  responses.  Very  similar  to  tumor  cells,  fetal  cells  do  not  ex‐
press classical MHC class I molecules, instead these cells express the non-classical HLA-
G molecules. The multiple immune suppressive properties of this molecule strongly imply
that  HLA-G is  part  of  a  tolerogenic  system.  HLA-G exerts  exclusively  immunossupres‐
sive functions, which impair both the innate as well as the acquired immunity by multi‐
ple mechanisms. Firstly, the immune effector functions of cytotoxic T lymphocytes and NK
cells  are  inhibited  in  the  case  of  target  cells  expressing  HLA-G  [44].  Secondly,  APC
expressing HLA-G, inhibit  the proliferation of  CD4+ T cells,  induce CD4+ T cell  anergy
and cause the differentiation of  CD4+ T cells  into regulatory cells  (Tregs),  which as  we
mentioned previously these cells possess the competence to inhibit the effector function of
other T cells.  Thirdly, the binding of HLA-G to DC results in disruption of DC matura‐
tion, in inhibition of antigen presentation, and in induction of immunosuppressive T cells.
Soluble HLA-G molecules fulfill the same tasks as membrane-bound ones. Beyond it sHLA-
G molecules are able to inhibit cell cycle progression in T lymphocytes and to mediate the
induction of apoptosis on activated T and NK cells [45].
HLA-G is unique in its heterogeneous and unusual molecular structure. Contrary to classical
MHC class I molecules HLA-G displays with 23 different alleles a limited polymorphism, in
which all amino acid exchanges are located outside the peptide binding groove. Therefore, the
diversity of peptides bound by HLA-G is very restricted relatively to classical class I molecules
[46]. Thus, it is very unlikely, that this molecule represents a target molecule for the T cell
receptor inducing the anti-tumor response. The lymphocyte differentiation marker CD8+ is a
classical receptor for MHC class I and as a co-receptor with the TCR during the recognition of
peptides being presented by MHC class I. Both, HLA-G and classical HLA class I molecules
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bind with the same affinity to CD8+. The engagement of sHLA-G molecules with CD8+ results
in the induction of apoptosis via the Fas/FasL pathway.
17. Immunotherapy in melanoma: Disappointing results
Recent progress toward an understanding of the interactions between the host’s immune
system and melanoma has led to the realization that tumor cells have devised many strategies
to evade the immune attack. Evasion mechanisms can either be pre-existing, arise through
outgrowth of escape mutants or take place during tumor-sculpting actions by the immune
system as was proposed in the “Cancer Immunoediting” hypothesis [47]. One of these
strategies of tumor-immune escape is represented by the acquistion of FasL expression that
may enable cancer cells to deliver death signals to activate Fas-positive T lymphocytes [48].
However, despite all the data accumulated in the support of the FasL counterattack hypothesis,
there are many studies in contradiction showing that FasL can also have proinflammatory
effects in some contexts [49]. To explain these conflicting findings, it is proposed that the
maintenance of immune privileged in tumors depend not only on FasL itsel but also on the
production of massive immunosuppressive factors (previously mentioned). The final outcome
of an effective antitumor response is determined by a delicate interplay among activating and
inhibitory regulatory pathways and the removal of inhibitory signals may be very useful in
addition to other therapeutic approaches.
Depending on the subtype of melanoma, patients with metastatic melanoma have a median
survival of 8 months and 1 year survival rates of 10 to 15%. The two FDA approved treatments
for melanoma are dacarbazine-based chemotherapy and IL-2 with objective response rates
below 18% [50]. Several clinical trials in stages IIB-IV of cutaneous melanoma utilizing
vaccination with multiple peptides derived from MART-1, gp-100, tyrosinase and MAGE had
very limited success in those patients [51].
Nonspecific therapies including the use of monoclonal antibodies against CTLA-4 have leaded
to some considerable responses, but this agent has low response rates (12% to 15%) in patients
with advanced melanoma.
Active therapeutic immunization has been pursued in clinical trials using a host of tumor
vaccines, but these have shown disappointing response rates [52]. The development of
therapeutic cancer vaccines is very complex, and it has been learned that stimulation and
suppression are the two sides to the coin of manipulation of the immune system and the latter
might be increased with the multiple use of a specific vaccine.
Cancer/testis (CT) antigens represent promising targets for immunotherapy because they are
expressed in a wide variety of epithelial cancers but are restricted in their expression in normal
adult tissues to cells in the testis which lack expression of MHC class I and are not susceptible
to damage by T cells that recognize these products. Other members of the CT family of antigens
include NY-ESO-1, LAGE-!, SSX1-5, CTp11, CT7, etc. Melanoma cells produce the CT antigens
at different frequencies, so more studies are needed to solve if some of these marker proteins
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might be useful in further clinical studies. The NY-ESO antigen is expressed in 15 to 40% of
highly prevalent tumors such as breast, lung, prostate and melanomas. To test the effectiveness
of adoptive immunotherapy with genetically engineered cells that target the NY-ESO-1
antigen, phase I clinical trials of cancer vaccines were tried using peptides [53], recombinant
vaccinia and fowlpox viruses encoding full-length NY-ESO-1 [54], or recombinant NY-ESO-1
protein [55], but have failed to demonstrate a clinical benefit in patients with advanced disease.
Adoptive cell therapy (ACT) using tumor reactive TILs following host lymphodepletion can
lead to objective responsive rates of around 40% and durable responses in patients with
refractory melanoma. This ACT used tumor antigen-specific lymphocytes that were initiated
in vitro from single-cell enzymatic digests or small fragments of resected tumor specimens and
expanded to large numbers before infusion [56]. However, this therapy requires sophisticated
cell processing and in vitro lymphocyte culturing for long periods. These requirements have
technical, regulatory, and logistic challenges that have limited the use of antigen specific TILs
as a biological therapy.
Recently, Rosenberg and his group, reported responses of around 45% in patients with
melanoma. In their adoptive immunotherapy trial to treat melanoma they used genetic
engineering of T cells to express a CT antigen-specific TCR. They reported great variation in
levels of T cell persistence between the patients and did not seem to be associated with clinical
response to therapy. These findings indicate that treatments using TCRs directed against NY-
ESO-1 are effective at mediating tumor regression in some patients (two of eleven patients
demonstrated complete regression that persisted after one year) [57]. Given the small number
of patients treated in their trial, it is difficult to evaluate the significance of these results.
18. Conclusion
The accumulated data indicate that the outcome of an immune response toward a tumor is
largely determined by the type of immune response elicited. A tumor-directed immune
response involving CD8+ T cells, CD4+ Th1 cells and NK appears to protect against tumor
development and progression.
The future looks promising for melanoma immunotherapy, even with the disadvantages that
researchers in the area and clinicians still face nowadays. Most vaccine trials have failed to
show an important response rate or an impact on survival. The overall situation, is problematic
and it has become clear that large tumors display a setting in which vaccination has a limited
role; the most amenable clinical context to assay antitumor vaccination, would be patients in
which the existence of micrometastasis, is highly probable. In this case, the immune system
has fewer obstacles to surmount. Melanoma patients with satges II and III of the disease could
benefit from such therapy.
Of note is the report by Robbins and coworkers in 2011, where they used an adoptive transfer
of autologous T cells transduced with a TCR directed against NY-ESO-1, a cancer/testis antigen
expressed in 40% of metastatic melanomas, but not in any normal adult tissues except the testis.
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They reported two of 11 patients with complete regressions that persisted after one year.Potential strategies that may enhance responses including immunization with recombinantvaccines encoding the NY-ESO-1 antigen, elimination of host Tregs and cotransduction of TCRconstructs with genes that encode cytokines such as IL-12 should be taken into account in thefuture.
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